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A B S T R A C T
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by
recurrent syncopes and sudden cardiac death triggered by sympathetic activation in young individuals
without structural heart disease and a normal baseline electrocardiogram. There is reason to question
whether the current expert consensus treatment recommendation, maximal tolerated b-blockade alone
or in combination with low-dose ﬂecainide, is the optimal antiarrhythmic treatment strategy in CPVT, as
high doses of b-blockers may eventually lead to adverse side effects and b-blocker discontinuation.
Indeed, b-blocker non-compliance accounts for around 5% of sudden cardiac deaths in CPVT patients.
Case report: Differing from the current recommendation, we present the ﬁrst report of a CPVT patient
successfully treated with high-dose ﬂecainide and minimal b-blockade. This combination resulted in
complete suppression of ventricular arrhythmias during exercise stress tests and Holter monitoring and
was well tolerated without any side effects. We review the current literature on b-blocker non-
compliance-related sudden cardiac death in CPVT, summarize the in vitro and in vivo data on ﬂecainide
therapy in CPVT, and discuss the rationale of our antiarrhythmic approach.
<Learning objective: This case illustrates typical features of CPVT including the therapeutic
management of a young CPVT patient with poor b-blocker tolerance at normal dosages. In this setting,
high-dose ﬂecainide combined with minimal b-blockade may (1) result in complete antiarrhythmic
response and may (2) improve the antiarrhythmic drug-compliance thereby reducing the risk of non-
compliance-related sudden cardiac death.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is an inherited arrhythmia syndrome characterized by
the occurrence of syncopes and sudden cardiac death (SCD) in
young individuals without structural heart disease and a normal
baseline electrocardiogram (ECG). Cardiac events are triggered by
sympathetic activation during emotional or physical stress
[1,2]. In 50–60%, a mutation in the cardiac ryanodine receptor* Corresponding author at: Department of Cardiology and Angiology I, Heart
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diastolic calcium release from the sarcoplasmic reticulum
through the defective (‘‘leaky’’) RYR2 channels, a cytosolic
calcium overload, subsequent delayed after-depolarizations
(DADs), and triggered activity, manifesting as ectopic beats,
bigeminy, and polymorphic or bidirectional ventricular tachycar-
dia, the hallmark of CPVT [1–3].
Since 2013, ﬂecainide has been included in the pharmacological
management of CPVT patients [4]. Flecainide appears to have RYR2
blocking properties, thus allowing direct targeting of ‘the
molecular defect’ in CPVT [5,6]. In a retrospective analysis of
33 CPVT patient histories, ﬂecainide in combination with standard
(mostly high-dose) b-blocker therapy has shown partial or
complete antiarrhythmic response in CPVT patients carrying
RYR2 or calsequestrin mutations [7]. Flecainide is now added ons reserved.
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therapy when antiarrhythmic control appears to be incomplete
[4]. However, high doses of b-blockers may eventually result in
adverse side effects in the course of the disease, leading to b-
blocker non-compliance, which accounts for around 5% of SCDs in
CPVT. Thus, there is reason to doubt that high-dose b-blockade
with addition of ﬂecainide is the optimal antiarrhythmic treatment
strategy in CPVT.
Case report
A 12-year-old teenager (156 cm, 40 kg) was training in a soccer
team at the time of CPVT diagnosis. No stress-related syncope had
been noted to date; however, there was a positive family history of
SCD. In 2005, one brother (the index patient) died at the age of
14 years during a soccer match due to ventricular ﬁbrillation; he
had experienced two episodes of syncope in the past, one while
swimming and the second in an emotionally stressful situation at
church. In 2011, molecular genetics revealed a novel pathogenic
RYR2 mutation (c. 6647A>C) in four out of six family members
(Fig. 1a and b), again prompting clinical evaluation of the family.
On exercise testing, the young girl showed polymorphic premature
ventricular complexes (PVCs), bigeminy, and couplets. A standard
b-blocker therapy with 2.5 mg bisoprolol per day was initiated,
but poorly tolerated due to pronounced fatigue, and the patient
discontinued the antiarrhythmic therapy for a while. On the next
visit, bisoprolol was reduced to a tolerable low dosage of 1.25 mg
and combined with ﬂecainide. The antiarrhythmic efﬁcacy of this
combination was veriﬁed in repetitive exercise stress tests
(modiﬁed Bruce protocol) and ﬂecainide was increased stepwise
to achieve complete antiarrhythmic response (Fig. 2). The lowest
ﬂecainide dosage (2  50 mg; 2.5 mg/kg body weight per day)
(Fig. 2a) could not suppress PVCs on exertion; starting at 165 bpm,
sustained ventricular bigeminy, but no couplets, were observed.
Increasing ﬂecainide to 2  75 mg (3.75 mg/kg body weight per
day) (Fig. 2b) reduced ventricular ectopy, and bigeminy occurred
only intermittently during the highest workload. On the thirdFig. 1.
(a) Pedigree of the affected family carrying the novel RYR2 mutation (p. Asp22
mutation carriers, crossed symbols denote deceased patients. The index patien
heterozygous RYR2 mutation c.6647 A>G; an exchange from adenine to guani
glycine (apolar amino acid) at position 2216 in a highly conserved region ofexercise stress test (Fig. 2c), a combined treatment with
2  100 mg ﬂecainide (5 mg/kg body weight per day) and
1.25 mg bisoprolol showed a complete suppression of catechol-
aminergic arrhythmias without a single PVC. These ﬁndings were
conﬁrmed by a 7-day Holter monitoring and at two further follow-
up stress tests 6 and 12 months later. The antiarrhythmic therapy
was well tolerated with no side effects.
Discussion
Conventional b-blockade has been the established therapy
since the ﬁrst reports of CPVT and the triggering role of
sympathetic activation [1,2]. However, b-blocker therapy has a
limited efﬁcacy in CPVT, with recurrence rates as high as 30%
[2]. Moreover, high doses of b-blockers are associated with adverse
side effects and several studies have shown that b-blocker non-
compliance accounts for around 5% of SCDs in CPVT (Table 1)
[1,2,8–11]. Indeed, skipping just a single b-blocker dose may result
in SCD of a CPVT patient [1,2]. Thus, it is critical to have an
antiarrhythmic treatment strategy in CPVT that is not only
effective, but also well-tolerated.
There is evidence suggesting that ﬂecainide monotherapy
may be sufﬁcient to suppress ventricular arrhythmias in CPVT.
Flecainide monotherapy resulted in complete suppression of
arrhythmias in cell and animal models [5,6,12] and in two CPVT
patients without causing any side effects [6,7]. Of note, high
ﬂecainide doses of up to 7 mg/kg body weight per day appear to
be safe and well-tolerated in infants and children with
supraventricular and ventricular tachycardias other than CPVT
and no structural heart disease [13]. While b-blockers aim to
attenuate the trigger of CPVT, i.e. sympathetic activation [3],
ﬂecainide acts more speciﬁcally and directly targets ‘the
molecular defect’ in CPVT. Two major antiarrhythmic modes of
action of ﬂecainide are postulated: (1) a direct blockade of RYR2
channels resulting in a reduced amplitude of DADs [5,14] and (2)
a blockade of luminal sodium channels resulting in an increased
threshold for triggered activity (with an unaffected DAD16Gly). Men are denoted by squares and women by circles. Solid symbols indicate
t is marked with an arrow. SCD, sudden cardiac death. (b) Electropherogram of the
ne leads to the amino acid substitution of aspartate (polar, negatively charged) by
 the RYR2 protein.
Fig. 2.
Exercise electrocardiograms (ECGs) of the young teenager recorded during maximal exertion (treadmill velocity 6.0 km/h at maximal treadmill gradient of 21%)
and increasing ﬂecainide dosages from (a) to (c) plus a constant low-dose b-blocker therapy. Vertical lines (red) in the exercise diagrams (bottom) indicate the
point when the corresponding ECGs (top) are taken. (a) Sustained bigeminy at a heart rate of 182 bpm during maximal exertion and a ﬂecainide dosage of 2.5 mg/
kg per day plus 1.25 mg bisoprolol. (b) Intermittent bigeminy at a heart rate of 180 bpm during maximal exertion and a ﬂecainide dosage of 3.75 mg/kg per day
plus 1.25 mg bisoprolol. (c) Sinus tachycardia without bigeminy at a heart rate of 150 bpm during maximal exertion and a ﬂecainide dosage of 5 mg/kg per day plus
1.25 mg bisoprolol. Of note, the arrhythmia suppression improved the patient’s exercise capacity allowing her to maintain the highest workload a bit longer.











Syncope or SCD related to
b-blocker non-compliance
Leenhardt, 1995 [1] 21 10 100% Nadolol 7 5%
Lahat, 2001 [8] 13 9 100% Propranolol 5 8%
Sumitomo, 2003 [9] 29 10 97% Propranolol 7 3%




Celiker, 2009 [11] 16 11 94% Propranolol 3 6%
Hayashi, 2009 [2] 101 15 80% Nadolol 8 7%
SCD, sudden cardiac death.
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ﬂecainide favors a combination of both drugs in CPVT; yet the
optimal ratio is not clear.
Differing from the current expert recommendation [4], we
report the ﬁrst CPVT patient successfully treated with high-dose
ﬂecainide and low-dose b-blockade. We increased ﬂecainide up to
5 mg/kg body weight per day to reach complete antiarrhythmic
response and reduced bisoprolol to minimize the incidence of
adverse side effects to obtain maximal compliance. Of note, a
ﬂecainide dosage of 5 mg/kg body weight per day constitutes the
highest ﬂecainide dosage in a CPVT patient with complete
antiarrhythmic response reported to date [7].Conclusions
The current understanding on the synergistic action of b-
blockers and ﬂecainide favors a combination of both drugs in
CPVT. However, high doses of b-blockers may cause adverse side
effects and may lead to non-compliance-related SCD in CPVT
patients. In our patient, high-dose ﬂecainide combined with low-
dose b-blockade resulted in complete suppression of ventricular
arrhythmias during exercise stress tests and Holter monitoring
and has been well tolerated without any side effects for more than
a year. The optimal ratio of the two drugs in CPVT has yet to be
deﬁned.
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